Fighting cancer with viruses – The Virotherapy

The oncolytic virotherapy destroys cancer cells using viruses and is a gentle and safe biological therapy. Life expectancy and the quality of life is increased, while side effects can be significantly reduced using an onkotropic and an oncolytic virus, which have not been genetically modified. The certified virotherapy used by Dr. Mohamed Ali Zayen from the Hyperthermia Centre Hannover is called RIGVIR® . A virotherapy is an outpatient treatment and follows an individually tailored treatment plan during a patients stay at the Hyperthermia Centre Hannover, Germany.

Dr. Mohamed Ali Zayen is a certified specialist of Virotherapy RIGVIR® at the Hyperthermia Centre Hannover. A Virotherapy consists of several injections provided to a patient and is given in accordance to a predetermined Virotherapy plan. After every injection into the body, the virus finds malignant tumor cells and destroys them using the RIGVIR® virus selectively (oncolysis). In the process, healthy cells are not damaged. Research undertaken by Professor Aine Muceniece shows that an ECHO-7 virus, as the most effective virus in oncolytic virotherapy.

The ECHO-7 virus is non-pathogenic and the virus is also not genetically engineered. In Latvia, the ECHO-7 virus from RIGVIR® is used since 2011 and approved for the treatment of malignant melanoma. Also in Latvia, a Virotherapy using RIGVIR® is paid for by the national health insurance. The Latvian Virotherapy Center in Riga / Latvia is researching the use of its RIGVIR® viruses for over 40 years.

RIGVIR® is injected intramuscularly and if possible near a lymph node.
As with most cancer therapies, it is utmost important to begin a therapy as soon as possible in order to minimize the risk of metastases. It is not uncommon, that an oncolytic Virotherapy begins way in advance of a surgery.
If no metastases are present, RIGVIR® is usually administered every 4 weeks for the first quarter. With metastases present, weekly injections or 3 injection in three days every 4 weeks for the first quarter are recommended and provided for by the Hyperthermia Centre Hannover.
Studies from Latvian Virotherapy Center in Riga/Latvia to RIGVIR® Virotherapy show that long term therapy plans represent the least risk of a relapse. The time intervals between injections might then be up to three (3) months. Of cause, thorough medical examinations including blood tests are provided for.
A Virotherapy has only mild side effects. The most common side effect is a slightly elevated body temperature, or a slight chill. Both can hold on for 1-3 days.
The effectiveness of oncolytic virotherapy has been studied and proved in many clinical studies. In Melanoma Research from Oct. 2015 Vol . 25 , 421-426 a retrospective investigation was published.
The study proves that the patients with melanoma in stage IIB – IIC have a 4-6 times longer life expectancy after a treatment with RIGVIR®, when compared to patients who received conventional melanoma therapy.

Main indications of oncolytic virotherapy with RIGVIR® are:

  • Melanoma
  • Stomach cancer
  • Colon cancer
  • Pancreas cancer
  • Kidneys cancer
  • Uterus cancer
  • Bladder cancer
  • Lung cancer
  • Prostate cancer
  • All types of sarcoma